Andrea Valencia-Orozco

Andrea Valencia-Orozco

Auto-generated profile, based on publicly available information

Andrea Valencia-Orozco

Centro de Investigaciones Clínicas, Fundación Valle del Lili, Cali 760032, Colombia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2023 in Global Heart
Verified
Journal Article
Open access
PDF file
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
SGStephania Galindo
Stephania Galindo
MEManuela Escalante-Forero
Manuela Escalante-Forero
YRYorlany Rodas
Yorlany Rodas
AVAndrea Valencia
Andrea Valencia
NFNoel Alberto Flórez
Noel Alberto Flórez
Background: Socioeconomic factors contribute to a more severe impact of COVID-19 in Latin American and Caribbean (LA&C) countries than in developed countries. Patients with a severe or critical illness can develop respiratory and cardiovascular complications. Objective: To describe a LA&C population with COVID-19 to provide information related to this disease, in-hospital cardiovascular complications, and in-hospital mortality. Methods: The CARDIO COVID-19–20 Registry is an observational, multicenter, prospective, and hospital-based registry of patients with confirmed COVID-19 infection that required in-hospital treatment in LA&C. Enrollment of patients started on May 01, 2020, and ended on June 30, 2021. Results: The CARDIO COVID-19–20 Registry included 3260 patients from 44 institutions of 14 LA&C countries. 63.2% patients were male and median age was 61.0 years old. Most common comorbidities were overweight/obesity (49.7%), hypertension (49.0%), and diabetes mellitus (26.7%). Most frequent cardiovascular complications during hospitalization or reported at discharge were cardiac arrhythmia (9.1%), decompensated heart failure (8.5%), and pulmonary embolism (3.9%). The number of patients admitted to the Intensive Care Unit (ICU) was 1745 (53.5%), and median length of their stay at the ICU was 10.0 days. Support required in ICU included invasive mechanical ventilation (34.2%), vasopressors (27.6%), inotropics (10.3%), and vasodilators (3.7%). Rehospitalization after 30-day post discharge was 7.3%. In-hospital mortality and 30-day post discharge were 25.5% and 2.6%, respectively. Conclusions: According to our findings, more than half of the LA&C population with COVID-19 assessed required management in ICU, with higher requirement of invasive mechanical ventilation and vasoactive support, resulting in a high in-hospital mortality and a considerable high 30-day post discharge rehospitalization and mortality.

13 May 2023 in Children
Verified
Journal Article
Open access
PDF file
GSGustavo Cruz Suarez
Gustavo Cruz Suarez
SGSantiago Pedroza Gómez
Santiago Pedroza Gómez
AAAkemi Arango
Akemi Arango
PGPaula A. Guevara
Paula A. Guevara
CGCarlos González
Carlos González
ASAntonio J. Suguimoto
Antonio J. Suguimoto
Multiple tissue perfusion markers are described to guide therapy in critically ill pediatric patients undergoing congenital heart surgery. Given the advantages of capillary refill time, our goal is to determine its predictive capacity for mortality and postoperative extracorporeal oxygenation requirements in congenital heart surgery and compare it to serum lactate. We conducted a prospective cohort observational study in a single high-complexity university hospital. Serum lactate and capillary refill time were measured at five predetermined time points: preoperative, immediate postoperative, 6, 12, and 24 h after the surgery. Prolonged immediate postoperative, 6 h, and 12 h capillary refill time measurements turned out to be independent risk factors for both outcomes. The capillary refill time area under the curve ranged between 0.70 and 0.80, while the serum lactate resulted between 0.79 and 0.92 for both outcomes. Both tissue perfusion markers resulted in mortality and extracorporeal oxygenation requirement predictors. Given the advantages of capillary refill time over serum lactate, a monitoring strategy including these two perfusion markers should be considered for congenital heart surgeries.

5 May 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
JAJuan Pablo Arango‐Ibanez
Juan Pablo Arango‐Ibanez
SSSebastián Seni‐Molina
Sebastián Seni‐Molina
JMJuan Andrés Muñoz-Ordoñez
Juan Andrés Muñoz-Ordoñez
VAValeria Azcárate‐Rodríguez
Valeria Azcárate‐Rodríguez
AVAndrea Valencia‐Orozco
Andrea Valencia‐Orozco
SMSebastian Seni Molina
Sebastian Seni Molina
Background: Acute heart failure (HF) frequently coexists with multimorbidity. Comorbidity clusters have been associated with distinct clinical outcomes, but data from the Americas remain limited. We aimed to identify comorbidity clusters in patients with acute HF and assess their association with in‐hospital outcomes. Methods: This cohort study applied latent class analysis to patients from the AMERICCAASS Registry (Registro Americano de Insuficiencia Cardiaca Ambulatoria o Agudamente descompensada). Adjusted Poisson regression assessed in‐hospital mortality and intensive care unit (ICU) admission, and multivariable analysis identified independent predictors of ICU admission. Results: Among 1638 patients, 60.6% were men and the median age was 67.2 years. Hypertension (69.4%), smoking (40.3%), and coronary artery disease (33.8%) were common comorbidities. Cluster 1 (Young, n=828) included the youngest patients (median age 63.2 years) with the fewest comorbidities. Cluster 2 (Cardio‐Kidney‐Metabolic, n=512) represented the oldest group (median age 71.8 years) with the highest median body mass index (27.7 kg/m 2 ), the greatest proportion of HF with mildly reduced or preserved ejection fraction (44.7%), and a high comorbidity burden. Cluster 3 (“Ischemic,” n=298) was characterized by older patients (median age 70.2 years) with an exceptionally high prevalence of coronary artery disease (96.3%) and the greatest proportion of HF with reduced ejection fraction (61.4%). ICU admission risk was higher in Cluster 2 (adjusted risk ratio [aRR], 1.15 [95% CI, 1.03–1.27]; P =0.009) and Cluster 3 (aRR, 1.25 [95% CI, 1.12–1.39]; P <0.001), compared with Cluster 1. Severe valvular insufficiency, peripheral artery disease, dyslipidemia, cancer, acute coronary syndrome, anemia, and cardiogenic shock were associated with higher ICU admission risk. Conclusions: Patients with acute HF in the Americas exhibit distinct comorbidity patterns associated with different clinical profiles and ICU admission rates, which may inform risk stratification and management strategies. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT05295641.

Verified
Journal Article
Open access
PDF file
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
MEManuela Escalante
Manuela Escalante
JMJuan Andrés Muñoz-Ordoñez
Juan Andrés Muñoz-Ordoñez
VAValeria Azcárate-Rodriguez
Valeria Azcárate-Rodriguez
Juan David Peláez-MartínezJuan David Peláez-Martínez
Juan David Peláez-Martínez
JMJORGE DANIEL SIERRA -LARA MARTINEZ
JORGE DANIEL SIERRA -LARA MARTINEZ
Background: The COVID-19 pandemic has highlighted a correlation between cardiac complications and elevated cardiac biomarkers, which are linked to poorer clinical outcomes. Objective: This study aims to determine the clinical impact of cardiac biomarkers in COVID-19 patients in Latin America. Subjects and methods: The CARDIO COVID 19-20 Registry is a multicenter observational study across 44 hospitals in Latin America and the Caribbean. It included hospitalized COVID-19 patients (n = 476) who underwent troponin, natriuretic peptide, and D-dimer tests. Patients were grouped based on the number of positive biomarkers. Results: Among the 476 patients tested, 139 had one positive biomarker (Group C), 190 had two (Group B), 118 had three (Group A), and 29 had none (Group D). A directly proportional relationship was observed between the number of positive biomarkers and the incidence of decompensated heart failure. Similarly, there was a proportional relationship between the number of positive biomarkers and increased mortality. In Group B, patients with elevated troponin and natriuretic peptide and those with elevated troponin and D-dimer had 1.4 and 1.5 times higher mortality, respectively, than those with elevated natriuretic peptide and D-dimer. Conclusions: In Latin American COVID-19 patients, a higher number of positive cardiac biomarkers is associated with increased cardiovascular complications and mortality. These findings suggest that cardiac biomarkers should be utilized to guide acute-phase treatment strategies.

Verified
Journal Article
Open access
PDF file
ASAlex David Sotomayor-Julio
Alex David Sotomayor-Julio
MEManuela Escalante
Manuela Escalante
YRYorlany Rodas-Cortes
Yorlany Rodas-Cortes
AAAndrea Arteaga-Tobar
Andrea Arteaga-Tobar
AVAndrea Valencia
Andrea Valencia
JGJuan Esteban Gómez-Mesa
Juan Esteban Gómez-Mesa
Background: An advanced age elevates risk for COVID-19-related cardiovascular complications and mortality. This study analyzes cardiovascular comorbidities and outcomes in hospitalized COVID-19 patients across age groups to assess its impact. Methods: The CARDIO COVID 19-20 registry is a prospective, multicenter cohort study of hospitalized SARS-CoV-2 patients across 44 institutions in 14 Latin American countries. Patients were categorized into four age groups, Group 1: under 40 years, Group 2: 40 to 64 years, Group 3: 65 to 79 years, and Group 4: 80 years or older. Results: A total of 3260 patients were included. A total of 36.8% were women, and key comorbidities included overweight/obesity (49.7% [G1: 48.9%, G2: 56.3%, G3: 45.6%, G4: 32.7%]), and hypertension (49% [G1: 11.3%, G2: 40.3%, G3: 67.9%, G4: 80.4%]). Primary cardiovascular complications during hospitalization were arrhythmias (9.1% [G1: 3.4%, G2: 6.1%, G3: 14.9%, G4: 12.9%]), and acute heart failure (8.5% [G1: 3.6%, G2: 6.1%, G3: 12.1%, and G4: 15.2%]). In our cohort, 53.5% of the patients were admitted to the intensive care unit (G1: 49.2%, G2: 57%, G3: 55.3%, G4: 38.3%). In-hospital mortality rose significantly in patients aged 65 and older; G3: 334 (34.7%) and G4: 156 (45.6%) (p value: <0.001). Conclusions: In Latin American COVID-19 patients, older age correlates with more comorbidities, cardiovascular complications, and higher in-hospital and 30-day mortality, indicating age as an independent mortality factor.

1 September 2026 in Journal of the American Heart Association
Verified
Journal Article
Closed access
SSSebastián Seni‐Molina
Sebastián Seni‐Molina
JAJuan Pablo Arango‐Ibanez
Juan Pablo Arango‐Ibanez
VVValentina Villegas‐Céspedes
Valentina Villegas‐Céspedes
AVAndrea Valencia‐Orozco
Andrea Valencia‐Orozco
HLHoover León-Giraldo
Hoover León-Giraldo
JSJosé Jesús Marval Saud
José Jesús Marval Saud
Background: Heart failure (HF) is a growing global health concern, particularly in low‐ and middle‐income countries. Contemporary, region‐specific data from the Americas remain scarce. The AMERICCAASS (Registro Americano de Insuficiencia Cardiaca Ambulatoria o Agudamente Descompensada [American Registry of Ambulatory or Acutely Decompensated Heart Failure]) registry was designed to provide broad, robust regional evidence on HF. Methods: The AMERICCAASS registry is a prospective, multicenter, observational study including adults with HF enrolled as inpatients or outpatients at 119 institutions in 21 countries across the Americas. Sociodemographic and clinical variables were summarized descriptively. Results: A total of 6732 patients were included; 30.1% were inpatients and 69.9% outpatients. The median age was 68.6 years, and 58.2% were men. Hypertension (69.6%), dyslipidemia (41.6%), and coronary artery disease (39.2%) were the most common comorbidities. Ischemic (39.9%) and hypertensive (17.9%) etiologies predominated, while Chagas disease was present in 3.4%. Unhealthy habits were common, with 39.8% reporting smoking, 24.4% alcohol use, and only 23.9% regular physical activity. New York Heart Association class III predominated in inpatients (45.2%), whereas New York Heart Association class II predominated in outpatients (52.6%). HF with reduced left ventricular ejection fraction was the most common phenotype in both settings: inpatients (56.8%) and outpatients (55.0%). β Blockers and mineralocorticoid receptor antagonists were the most frequently prescribed therapies, followed by sodium–glucose cotransporter‐2 inhibitors. Among inpatients, intensive care unit admission occurred in 55.9%, and the in‐hospital mortality rate was 7%. Conclusions: The AMERICCAASS registry offers a comprehensive overview of HF in the Americas. Although patient profiles were broadly consistent with global trends, important regional features were observed, including frequent unhealthy lifestyle habits and underuse of key therapies. The high prevalence of HF with reduced left ventricular ejection fraction, together with elevated intensive care unit admission rates and in‐hospital death, suggests potential gaps in care and underscores the need to further evaluate HF care delivery across the region. Registration: URL: clinicaltrials.gov ; Unique Identifier: NCT05295641.